← Back to Search

Monoclonal Antibodies

Atezolizumab + Bevacizumab for Rare Cancers

Phase 2
Waitlist Available
Led By Kanwal P Raghav, MD
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Liver and kidney function within specified limits
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Must not have
Various medical history exclusions including autoimmune diseases, organ transplantation, pulmonary conditions, infectious diseases, and cardiovascular conditions
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 years
Awards & highlights

Summary

This trial is studying how well atezolizumab and bevacizumab work in treating patients with rare solid tumors.

Who is the study for?
This trial is for patients with rare solid tumors like certain types of lung, anal, cervical, and other cancers. Participants must have measurable disease growth, adequate liver/kidney function, and be able to follow the study plan. They should not have severe allergies or autoimmune diseases, recent cancer treatments or investigational therapies within 28 days prior to the study.
What is being tested?
The trial tests how well atezolizumab (an immunotherapy drug) combined with bevacizumab (a drug that inhibits blood vessel growth in tumors) works against various rare solid tumors. It's a phase II study focusing on the effectiveness of these monoclonal antibodies in stopping tumor growth.
What are the potential side effects?
Potential side effects include immune-related reactions such as inflammation in organs; infusion reactions; increased risk of infections; possible bleeding issues due to interference with blood vessel formation; fatigue; and allergic responses.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My liver and kidney are working well.
Select...
I am fully active or restricted in physically strenuous activity but can do light work.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have autoimmune diseases, organ transplants, serious lung, infectious, or heart conditions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Duration of response
Incidence of adverse events
Objective response
+2 more
Other study objectives
Predictive and prognostic biomarkers in blood and tumor tissue

Side effects data

From 2021 Phase 1 & 2 trial • 24 Patients • NCT03010358
33%
Infusion Related Reaction
33%
Alanine aminotransferase increased
33%
Aspartate aminotransferase increased
33%
Neutrophil count decreased
17%
Sinusitis
17%
Tumor Lysis Syndrome
17%
Interoperative Hemorrhage
17%
Platelet count decreased
17%
Febrile neutropenia
17%
Infusion related reaction
17%
Upper respiratory infection
17%
Otitis externa
100%
80%
60%
40%
20%
0%
Study treatment Arm
Phase 1, Dose 1 (400 mg Entospletinib Daily)
Phase 2 and MTD (800 mg Entospletinib Daily)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (atezolizumab, bevacizumab)Experimental Treatment4 Interventions
Patients receive atezolizumab and bevacizumab IV over 60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bevacizumab
2013
Completed Phase 4
~5540
Atezolizumab
2017
Completed Phase 3
~5850

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,842 Previous Clinical Trials
41,002,867 Total Patients Enrolled
22 Trials studying Cervical Carcinoma
30,355 Patients Enrolled for Cervical Carcinoma
M.D. Anderson Cancer CenterLead Sponsor
3,039 Previous Clinical Trials
1,799,568 Total Patients Enrolled
2 Trials studying Cervical Carcinoma
219 Patients Enrolled for Cervical Carcinoma
Kanwal P Raghav, MDPrincipal InvestigatorM.D. Anderson Cancer Center

Media Library

Atezolizumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT03074513 — Phase 2
Cervical Carcinoma Research Study Groups: Treatment (atezolizumab, bevacizumab)
Cervical Carcinoma Clinical Trial 2023: Atezolizumab Highlights & Side Effects. Trial Name: NCT03074513 — Phase 2
Atezolizumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03074513 — Phase 2
~16 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top